



# **Journal of Global Pharma Technology**

Available Online at: www.jgpt.co.in

#### **RESEARCH ARTICLE**

# Synthesis, Characterization and Biological Evaluation of Esters Derived from Sulfamethoxazole Drug

## Sameaa J. Khammas<sup>1</sup>, Inas S. Mahdi<sup>2\*</sup>, Selvana Adwar Yousif <sup>1</sup>

- 1. College of Science for Women/University of Baghdad/Baghdad/Iraq.
- <sup>2</sup> College of Agricultural Engineering Science/University of Baghdad/Baghdad/Iraq.

## \*Corresponding Author: Inas S. Mahdi

#### Abstract


A series of novel esters compounds have been prepared from the reaction of sulfamethoxazole drug with α-chloro acetyl chloride then reaction of the resulting compound with various carboxylic acids and carboxylic drugs. The modern ester has been diagnosed by ¹HNMR, FTIR spectral data and their physical properties and some of them were screened for their antibacterial activity.

**Keywords:** Sulfamethoxazole, Esters, Antibacterial activity.

#### Introduction

Sulfamethoxazole is a 4-amino-N-(5-methylisoxazol-3-yl) benzene sulfonamide,

the molecular formula for it  $(C_{11}H_{12}N_3O_3S)$  (SMX) and has structure as shown below [1]:



It is in the type of sulfonamide that are widely utilized as antibacterial substance, because they overlap with p-amino benzoic acid (PABA)in the biosynthesis tetrahydrofolic acid which is important for bacteria-Monti in the metabolic operation [2].A creation of hydrofolic acid is necessary for bacteria in order to survive [3,4]. Mixture sulfamethoxazole and trimethoprim (SMX/TMP) which isknown as cotrimoxazole is utilized to treat a broad of variety bacterial infection e.g.: (genitourinary tract infections), (middle ear infections), (respiratory-tract infections such as bronchitis and enteric infections).

The combination is also used to prevent and treat a certain type of pneumonia (pneumocystis-type) [5, 6]. As with any other drug there are some side effects maybe appear when use (SMX/TMP) such as: gastrointestinal upset and rash [7]. SMX work as (acid and base) as base because of presence the primary amine having pKa

(1.39) and being acidic because of presence the secondary amine with pKa (5.81) [8]. Accordingly, we wish to report herein the synthesis of new esters with diverse heterocyclic ring and investigate its biological significance.

## **Experimental**

### **Instruments**

Melting points were registered by using {Stuart Melting Point apparatus}. Infrared **FTIR** {Shimadzu -8300 spectra Spectrophotometer} in Ibn Sina State Company (ISSC).¹HNMR spectra written down on {Bruker-400 MHz} with used (TMS) as interior standard in DMSO-d6 as a solvent in AL- albayt University-Jordon.

# Methods

Synthesis of {2-chloro-N-(4-(N-(5-methylisoxazol-3-yl)sulfamoyl)phenyl) acetamide} (C<sub>1</sub>) [9]

Put in a suitable round a mixture of (0.016 mole) sulfamethoxazole drug and (10ml) DMF with (0.025mole) triethyl amine then added (0.016 mole) chloro acetyl chloride drop-wise in 5-10°C and stirred for (6 hr). The resulting solid filtered, dried then recrystallized by ethanol.

# General Method for Synthesis of Esters by the Reaction of Compound (1) with Carboxylic Acids and Carboxylic Drugs (C<sub>2</sub>-C<sub>11</sub>) [10]

A mixture from (0.01mole) compound (1) and (0.01 mole) carboxylic acid (*p*-nitro benzoic acid, *m*-nitro cinnamic acid, *p*-chloro benzoic acid, benzoic acid, 3,5-dinitro benzoic acid) mixed with (0.011 mole) sodium iodide and (0.011mole) trimethylamine in (10 ml)DMF has been refluxed at 90°C for 3hrs.The resulted precipitate has been filtered and dried. The same method has been repeated with carboxylic drugs (Naproxen, Ibuprofen,

Ciprofloxacin, Mefenamic acid, Ampiciline). Physical properties for a new compound listed in Table (1).

## **Antibacterial Activity Test [11]**

A cup plate process using nutrient agar medium was used in examine the antibacterial activity for some prepared compounds against two type of bacteria, Staphylococcus aureus(gram+ ve) & Escherichia coli(gram-ve) respectively and DMSO has been used as a sample solution.

A sterilized cork borer cups was used and has been scooped in a petri dish out of agar medium which has been formerly vaccinated with microorganisms, the verified compound solution(0.1ml) has been poured in the cups then the petri dishes has been afterward brood at(37°C) for 48hrs. Zones of inhibition have been calculated in (mm), the results registered in Table (4).

$$H_2N$$
 $H_2N$ 
 $H_3N$ 
 $H_3N$ 

Scheme 1: Synthetic route for new esters

### **Results and Discussion**

Esters can be prepared by refluxing compound (1) with carboxylic acids and drugs, Scheme(1).In general the new derivatives was characterized by physical properties, spectroscopic data, Tables (1),(2),(3). The FTIR spectrum of compound (4), Figure (9) shows bands at: (1681) cm<sup>-1</sup>

back to  $\upsilon(C=O)$  ester,(1161,1319)cm<sup>-1</sup>for  $\upsilon(SO_2)$ and at(3444)cm<sup>-1</sup>, (763)cm<sup>-1</sup>for  $\upsilon(NH)$  and  $\upsilon(C-Cl)$  respectively. Compound (6), Figure (10) shows in addition to the above absorption bands a stretching band at (1346-1543) cm<sup>-1</sup> due to  $\upsilon(NO_2)$  group. Figure (11) showed FTIR spectrum of compound (7).

FTIR spectrum of compound (9), Figure (12) shows absorption brigades at: (1732), (877) to  $\upsilon(C=O)$ cm<sup>-1</sup> owned ester,  $\upsilon(C-F)$ respectively.

<sup>1</sup>HNMR spectral data of ester (3), Figure(13) exhibit signs at  $(\delta \text{ ppm})$ : (2.2) due to (CH)imidazole ring, (2.4) due to (CH<sub>3</sub>)imidazole ring (2.9) due to (CH<sub>2</sub>) Neighboring carboxyl group, (3.1) due to (CH=CH), (5.8) due to (NH) near sulfoxide group, (6.1) due to (NH)amide and multiple signals at (6.5-8.5) due to aromatic rings protons. <sup>1</sup>HNMR spectrum of compound (4), Figure (14) showed diagnostic signals at (δppm): (2.1) due to (CH<sub>2</sub>), (2.4) due to (CH<sub>3</sub>), (6.5) due to (NH) amide and the protons of aromatic rings appeared at (6.8-8.4). Figure (15) showed the <sup>1</sup>HNMR spectrum of compound (7), these signals and others has been registered in Table (3).

Table 1: Physical properties for prepared compounds (1-11)								
Comp. No.	Molecular Formula M.wt.(gm/mol)	Nomenclature	-R	Yield %	Color	м.Р°С		
1	C <sub>12</sub> H <sub>12</sub> ClN <sub>3</sub> O <sub>4</sub> S 329.76	2-chloro-N-(4-(N-(5- methylisoxazol-3-yl) sulfamoyl)phenyl)acetamide	-	78	Biege			
2	C <sub>19</sub> H <sub>16</sub> N <sub>4</sub> O <sub>8</sub> S 460.42	2-(4-(N-(5-methylisoxazol-3-yl)sulfamoyl)phenyl amino)- 2-oxoethyl-4-nitrobenzene	O <sub>2</sub> N—	62	Light brown	Oily		
3	C <sub>21</sub> H <sub>18</sub> N <sub>4</sub> O <sub>8</sub> S 486.45	2-(4-(N-(5-methylisoxazol-3-yl)sulfamoyl)phenyl amino)- 2-oxoethyl-3-(3-nitrophenyl) acrylate	C=C- H H	65	Dark brown	Oily		
4	C <sub>19</sub> H <sub>16</sub> ClN <sub>3</sub> O <sub>6</sub> S 449.86	2-(4-(N-(5-methylisoxazol-3-yl)sulfamoyl)phenyl amino)- 2-oxoethyl-4-chlorobenzoate	CI	74	Dark brown	Oily		
5	C <sub>19</sub> H <sub>17</sub> N <sub>3</sub> O <sub>6</sub> S 415.42	2-(4-(N-(5-methylisoxazol-3-yl)sulfamoyl)phenyl amino)- 2-oxoethyl benzoate		77	Reddishbrown	Oily		
6	C <sub>19</sub> H <sub>15</sub> N <sub>5</sub> O <sub>10</sub> S 505.41	2-(4-(N-(5-methylisoxazol-3-yl)sulfamoyl)phenylamino)-2-oxoethyl-3,5-dinitrobenzoate	$O_2N$ $O_2N$	72	Reddishbrown	Oily		
7	C <sub>26</sub> H <sub>25</sub> N <sub>3</sub> O <sub>7</sub> S 523.56	2-(4-(N-(5-methylisoxazol-3-yl)sulfamoyl)phenylamino)-2-oxoethyl-2-(6-methoxynaphthalin-2-yl) propanoate	H <sub>3</sub> C — O — CH <sub>3</sub>	85	Orange	114-116		
8	C <sub>25</sub> H <sub>29</sub> N <sub>3</sub> O <sub>6</sub> S 499.58	2-(4-(N-(5-methylisoxazol-3-yl)sulfamoyl)phenylamino)-2-oxoethyl-2-(4-isobutyl phenyl)propanoate	H <sub>3</sub> C H H <sub>2</sub> CH <sub>3</sub> CH <sub>3</sub> H <sub>3</sub> C H H <sub>2</sub> CH <sub>3</sub>	81	Orange	119-120		
9	C <sub>29</sub> H <sub>29</sub> FN <sub>6</sub> O <sub>7</sub> S 624.64	2-(4-(N-(5-methylisoxazol-3-yl)sulfamoyl)phenylamino)-2-oxoethyl-1-cyclopropyl-6-floro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylate	F N N N N N N N N N N N N N N N N N N N	73	White	180-182		
10	C <sub>27</sub> H <sub>26</sub> N <sub>4</sub> O <sub>6</sub> S 534.58	2-(4-(N-(5-methylisoxazol-3-yl)sulfamoyl)phenylamino)-2-oxoethyl-2-(2,3-dimethyl phenylamino)benzoate	CH <sub>3</sub>	70	Orange	160-162		

$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	(4-(N-(5-methylisoxazol-3-sulfamoyl)phenylamino)-2-bethyl-6-(2-amino-2-phenyletamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicycle[3,2,0]heptan-2-carboxylate	NH <sub>2</sub> HC C N S CH <sub>3</sub> CH <sub>3</sub>	69	Dark Orange	177-179	
-------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------	----------------------------------------------------------	----	-------------	---------	--

Comp.	υ(C=O)	υ(C=N)	υ(C=C)	υ(C-H)cm <sup>-1</sup>	υ(Ar-H)	υ(C-N)	υ(C-O)	Other Band
No.	$\mathbf{cm}^{\text{-}1}$	cm-1	$\mathbf{cm}^{\text{-}1}$	aliphatic	$\mathbf{cm}^{ ext{-}1}$	cm <sup>-1</sup>	cm-1	cm <sup>-1</sup>
1	1681	1612	1500	(2831-	(3047-	1495	1261	υ(SO <sub>2</sub> ) 1165, 1396
1	1001	1012	1543	2985)	3170)	1495	1334	υ(N-H) 3232, 3321
			1508	(2804-	(3062-		1296	υ(SO <sub>2</sub> ) 1165, 1346
2	1701	1658	1520	2993)	3120)	1462	1307	υ(NO <sub>2</sub> ) 1369, 1527
	1701		1520	2993)	3120)		1307	υ(N-H) 3471
				(2873-	(3016-		1280	υ(SO <sub>2</sub> ) 1145, 1311
3	1701	1616	1597	2981)	3043)	1419	1311	υ(NO <sub>2</sub> ) 1357, 1527
			ļ	2981)			1311	υ(N-H) 3451
				(2808-			1373	υ(SO <sub>2</sub> ) 1161, 1319
4	1681	1616	1593	2978)	3051	1465	1373	υ(N-H) 3444
				2310)			1332	υ(C-Cl) 763
				(2870- 2981)	3051	1462	1377	
5	1689	1616	1597					$\upsilon(SO_2)$ 1157, 1319
				2301)				υ(N-H) 3441
		1620	1597	(2873- 2981)	3043 3093	1465	1265	$\upsilon(SO_2)$ 1161, 1323
6	1701							υ(NO <sub>2</sub> ) 1346, 1543
				,				υ(N-H) 3464
7	1728	1620	1597	(2769-	3143	1469	1311	$\upsilon(SO_2)\ 1157,\ 1365$
•	1678	1020	1001	2974)	3182	1100	1011	υ(N-H) 3468
8	1720	1620	1597	(2870-	3140	1495	1369	υ(SO <sub>2</sub> ) 1161, 1319
	1120	1020	1001	2954)	0140	1400	1000	υ(N-H) 3468
				(2870-				υ(SO <sub>2</sub> ) 1041, 1392
9 17	1732	1732 1627	1508	2951)	3024	1485	1330	υ(N-H) 3990
								υ(C-F) 887
10	1725	1725 1620	1597	(2989-	3143	1469	1315	υ(SO <sub>2</sub> ) 1157, 1369
	1,20	1020	1001	3007)	0110	1100	1010	υ(N-H) 3441
	1740	1628	1590	(2870- 2960)	3077	1460		υ(SO <sub>2</sub> ) 1141, 1320
11							1310	υ(N-H) 3400
								υ(NH <sub>2</sub> ) 3450,3471

Table 3: 1HNMR spectral information for esters (C3, C4, C7)

Comp. No.	¹HNMR spectral information δ ppm
3	2.2(s,1H,CH imidazole ring); 2.4(s,3H,CH <sub>3</sub> ); 2.9(s,2H,CH <sub>2</sub> ); 3.1(d,2H, CH=CH ethylene group);5.8(s,1H,NH sulfoxide);6.1(s,1H,NH amide);(6.5-8.5)(m,8H,Ar-H)
4	2.1(s,2H,CH <sub>2</sub> );2.4(s,3H,CH <sub>3</sub> );(2.8-3.5)(m,1H,NH imidazole ring);6.1(s,1H,NH); 6.5 (s,1H,NH amide);(6.8-8.4)(m,8H,Ar-H)
7	1.4(s,1H,CH);2.4(s,3H,CH <sub>3</sub> );2.9(s,2H,CH <sub>2</sub> );3.4(s,3H,CH <sub>3</sub> imidazole ring);3.9(s,3H,O-CH <sub>3</sub> ); 6.1(s,1H,NH imidazole);6.5(s,1H,NH amide);(7.5-8.4)(m,8H,Ar-H)

#### Antibacterial Activity Study [12]

biological activities have been determined by measuring the diameter around the well (Inhibition zone). From the data obtained it is clearly that compound (C<sub>2</sub>) showed moderate to low activity against Escherichia coli and inactive against Staphylococcus aureus. Compounds (C<sub>3</sub>), (C<sub>4</sub>) and (C<sub>7</sub>) possess moderate activity against Staphylococcus aureus in high concentration and inactive against Escherichia coli, while (C<sub>8</sub>) showed moderate activity against both types of bacteria in high concentration only, and finally compound (C9) showed highest activity against both types of bacteria at all concentrations. The results of antibacterial studies have been registered in Table (4).

Table 4: Antibacterial activity data of Sulfamethoxazole and prepared compounds

Tubic ii iiii	oacteriar activity	auta of Samameth	onuzoic una prepa	rea compounas			
Comp. No.		Gram positive		Gram negative			
	S	taphylococcus aure	eus	Escherichia coli			
	C	onc. of extract gm/	/ml	Con. of extract gm/ml			
	0.1	0.01	0.001	0.1	0.001	0.001	

SMX	20	18	15	20	15	14
$C_2$	-	-	=	11	9	9
$C_3$	10	Ē	=	=	≣	=
$\mathbf{C_4}$	12	-	-	-	-	-
$\mathbf{C}_{7}$	12	8	-	-	-	-
$C_8$	14	11	-	15	-	-
C <sub>9</sub>	34	34	34	35	35	35



Fig.1: Effect of (C<sub>4</sub>) on "Staphylococcus"




Fig.2: Effect of (C<sub>4</sub>) on "E.coli"




Fig.3: Effect of (C<sub>7</sub>) on "Staphylococcus"




Fig.4: Effect of (C<sub>7</sub>) on "E.coli"




Fig.5: Effect of (C<sub>8</sub>) on "Staphylococcus"




Fig6: Effect of (C<sub>8</sub>) on "E.coli"



Fig.7: Effect of (C9) on "Staphylococcus"




Fig. 8: Effect of (C<sub>9</sub>) on "E.coli"




Figure 9: Spectrum of (C<sub>4</sub>) by used FTIR




Figure 10: Spectrum of (C<sub>6</sub>) by used FTIR




Figure 11: Spectrum of (C7) by used FTIR




Figure 12: Spectrum of (C<sub>9</sub>) by used FTIR




Figure 13: Spectrum of (C<sub>3</sub>) by used <sup>1</sup>HNMR




Figure 14: Spectrum of (C<sub>4</sub>) by used <sup>1</sup>HNMR




Figure 15: Spectrum of (C<sub>7</sub>) by used ¹HNMR

#### References

- Sulfonamides in Veterinary Drug Therapy, Barragry TB, Lea Febiger (1994) Philadelphia, Baltimore, Hong Kong, London, Munich, Sydney, Tokyosayfa 297. Chapter 12.
- Agwara MO, Ndifon PI, Ndosiri NB, Paboudam AG, Yufanyi DM, Muhamadou A (2010) Bulletin of Chemical Society of Ethiopia, 24 (23): 383-389.
- 3. AL-Tamimi EQ, Al-Issa MA, Al-Gburi HF (2013) J. Baghdad for Sci., 10 (3): 673-685. https://www.ajol.info/index.php/bcse/article/view/60680.
- 4. AL-Farajy GHA (2003) Thesis, College of Science, University of Baghdad. https://www.iasj.net/iasj?func=fulltext&aI d=77741
- 5. Sohrabi M, Fathabadi M, Nouri A (2010) Journal of Applied Chemical Research, 3 (12):47-52.
- 6. Dinc E, Kadioglu Y, Demirkaya F, Baleanu D (2011) J. Iran. Chem. Soc., 8 (1):90-91. https://www.researchgate.net/publication/216354534.

- 7. Ho JM, Juurlink DN (2011) CMAJ, 16: 183 http://www.cmaj.ca/content/183/16/1851.lo ng.
- 8. Toronto (2005) Advanced Chemistry Development Inc. ACD/Chem Sketch with pKa and Log D batch 9: 04.
- 9. AL-Majidi SMH (2013) Journal of AL-Nahrain University 67-79. https://www.researchgate.net/publication/322487 508.
- 10. Nahlini CN, Ramachandran S, Kavitha K (2011) International Journal of Research Pharmaceutical and Biomedical Science,

- 1112-1117. https:// www. research gate.net/publication/267386518.
- 11. KM Muhammad, MR Ahmed, MH Mahmoud (2017) Tikrit Journal of Pure Science, 22 (2):67-81. http:// tjps.tu.edu.ig/index.php/j/article/view/510/500.
- 12. AS Hassan (2006) Msc. thesis, Chem. Dep. College of Sci. Uinv. of Baghdad.
- 13. Spectrophotometric identification of organic compounds, Silverstien PM, Bassler GC (1963) 3<sup>rd</sup> ed., U. K. Academic press.